Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linda Lutgen-Dunckley"'
Autor:
Hong Yuen Wong, Zachary Brumberger, Michael J. Nemeth, Adam R. Karpf, Junko Matsuzaki, Brandon L. Martens, Justin Kocent, Linda Lutgen-Dunckley, Austin Miller, Kunle Odunsi, Eunice S. Wang, Gregory W. Roloff, Benjamin E. Paluch, Pragya Srivastava, Christopher S. Hourigan, Elizabeth A. Griffiths
Publikováno v:
Clinical Cancer Research. 24:1019-1029
Purpose: Treatment options are limited for patients with high-risk myelodysplastic syndrome (MDS). The azanucleosides, azacitidine and decitabine, are first-line therapy for MDS that induce promoter demethylation and gene expression of the highly imm
Autor:
Monica L. Guzman, Matthew Johnson, Hannah R.S. Fay, Tara Cronin, Joseph R. Moberg, Brandon L. Martens, Kaitlyn M. Dykstra, Linda Lutgen-Dunckley, Eunice S. Wang
Publikováno v:
Blood. 134:1278-1278
Background: Leukemia stem cells (LSCs) and acute myeloid leukemia (AML) blasts persisting in the bone marrow (BM) after chemotherapy are key drivers of AML relapse and chemotherapy refractoriness. The hypoxic microenvironment of the BM is known to pr
Autor:
Monica L. Guzman, Matthew Johnson, Tara Cronin, Brandon L. Martens, Kaitlyn M. Dykstra, Eunice S. Wang, Linda Lutgen-Dunckley
Publikováno v:
Blood. 132:3948-3948
Background: Despite initial responses to standard chemotherapy, most patients with acute myeloid leukemia (AML) relapse and have poor prognoses after subsequent therapy. The hypoxic bone marrow (BM) microenvironment is hypothesized to contribute to c
Autor:
Claire Fritz, Eunice S. Wang, Linda Lutgen-Dunckley, Callum M. Sloss, Scott Portwood, Krystal Watkins, Tara Cronin, Brandon L. Martens, Yelena Kovtun, Julie Adams, Sharlene Adams
Publikováno v:
Blood. 132:2647-2647
Background CD123 (IL-3 receptor alpha-chain) is a therapeutic target for hematological malignancies based on high expression levels in acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other cancers. The anti-CD1